BiotechTube

oxetacaine, aluminium and magnesium hydroxide + oxetacaine + magnesium and aluminium hydroxide

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Radiation-induced Oesophagitis

Conditions

Radiation-induced Oesophagitis

Trial Timeline

Apr 1, 2011 → Jan 1, 2017

NCT ID
NCT01336530

About oxetacaine, aluminium and magnesium hydroxide + oxetacaine + magnesium and aluminium hydroxide

oxetacaine, aluminium and magnesium hydroxide + oxetacaine + magnesium and aluminium hydroxide is a phase 3 stage product being developed by Viatris for Radiation-induced Oesophagitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01336530. Target conditions include Radiation-induced Oesophagitis.

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01336530Phase 3Terminated

Competing Products

2 competing products in Radiation-induced Oesophagitis

See all competitors
ProductCompanyStageHype Score
Pirfenidone Capsules （400 mg） + Pirfenidone Capsules（600mg） + Pirfenidone Capsules（0mg）Sun PharmaceuticalPhase 2/3
45
AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)MeiraGTxPhase 1
23